Models for Medical Affairs (MA) Unit – in BioPharma & MedTech

Our Consulting & Engagement Process:

1) System Dynamics, Agent and Discrete-Event Models of Medical Affairs functions
2) Diagnostics (current maturity level of Medical Affairs)
3) Strategy & RoadMap (for target maturity level of Medical Affairs)
4) Assessment (at defined intervals)
5) Maturity Model Evaluation

Sample Modeling Problems in Medical Affairs:

Model 1) A Model depicting Changing Role of Medical Affairs in Digital, Agile Pharma

Model 2) A Model depicting Collaboration – Digital and Agile Pharma demands Collaboration between RnD, Medical and Commercialization teams

Model 3) How can a Pharma (in APAC region) transform its Medical Affairs functions – from Sales to Medical Affairs Dept. with more agility and strategic roles?
a) Need to simulate the transformation strategy
b) Need to evaluate the business strategy
As medical affairs take a more broader and strategic role in Pharma, how leaders in APAC can fulfill the required capabilities and talent?

Complex, Adaptive System – A Pharma company
Agents – Internal agents within Pharmaco,
External main agents (HCP, KOL, Payer, Patient, Patient advocacy groups), Processes within Pharmaco, External main processes

1) Medical Affairs (within PharmaCo) as an Agent
a) State (variables, parameters)
b) Behaviour (statecharts)
c) End goals:
//Demonstrate Clinical and Economic benefits to Health Systems
//Patient Engagement
//Payor Engagement
//More Medical (within Ecosystem)
d) Means to achieve these goals
//Digital (within PharmaCo and within Ecosystem)
//Data-driven (within PharmaCo and within Ecosystem)
//Strategic/Broader roles (within PharmaCo)
//Talent/Capability development (within MA)
//Agile collaboration with RnD & Commercials
e) Pre-requisites:
//Definition and Approach to “Clinical and Economic benefits” needed by Health Systems
//Definition and Approach to “patient-centric”
//Definition and Approach to “payor-centric”
//Definition and Approach to “More Medical”
//Definition of “Digital”
//Definition of “Data/Analytics” driven
//Definition of “Strategic/Broader roles”
//Definition of “Talent/Capability” requirements
//Definition of “Agility”
2) MA Agent interaction with RnD & Commercials Agents (within PharmaCo)
3) Demonstrate use of multi-paradigm model architectures
a) Consider using different modelling paradigms for different parts of the simulation model
4) Why Agent-oriented design and modelling should be used for AI strategy/design and How to go about? (Simulation & Modeling of ABS, Artificial Intelligence for Agents)
a) Application of Design principles for Autonomous agents
b) How to design/develop/test an AI system
c) Architectures and Frameworks for Agents and Environments
d) Agent-oriented programming languages and Agent-directed simulations
5) How System Dynamics modelling (stock&flow diagrams) helps in identifying feedback loops, delays, stocks and flow rates to come up with better strategies.
6) How Discrete Event modelling (process flowcharts) can be done for various processes, aiding in process re-engineering, RPA, AI for decision support, technology enabling etc.
a) How Process Mining (Automated Process Discovery from Data) helps in discovering existing processes
b) How the existing processes can be re-engineered to include automation, AI, technology enablement etc.
7) How all these modelling/simulation/analysis techniques reveal highest leverage areas (for AI, automation, optimization etc.)
8) How this model can be integrated with real-world data to perform as a digital twin
9) How we can integrate AI with Simulation modelling
10) Proposed uses of this multi-model architecture

Background on Multi-paradigm model architecture:
//The processes inside the company are modelled in system dynamics terms
//Communication between the companies is essentially discrete
//The model of a particular process is extended to capture the bigger lifecycles of involved agents. Agents live in the environment (jobs, offices, patient facing etc.) whose dynamics is described in SD terms

Model 4) Strategy comparison on how it can transform – Which are the supporting areas where it can partner or invest (e.g. customised content platforms)

Model 5) A Model depicting Medical affairs in APAC

Model 6) A Model depicting Relationship between Medical Affairs and RWE